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A B S T R A C T
Background
Terminally ill people experience a variety of symptoms in the last hours and days of life, including delirium, agitation, anxiety, terminal
restlessness, dyspnoea, pain, vomiting, and psychological and physical distress. In the terminal phase of life, these symptomsmay become
refractory, and unable to be controlled by supportive and palliative therapies specifically targeted to these symptoms. Palliative sedation
therapy is one potential solution to providing relief from these refractory symptoms. Sedation in terminally ill people is intended to
provide relief from refractory symptoms that are not controlled by other methods. Sedative drugs such as benzodiazepines are titrated
to achieve the desired level of sedation; the level of sedation can be easily maintained and the effect is reversible.
Objectives
To assess the evidence for the benefit of palliative pharmacological sedation on quality of life, survival, and specific refractory symptoms
in terminally ill adults during their last few days of life.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2014, Issue 11), MEDLINE (1946 to November 2014),
and EMBASE (1974 to December 2014), using search terms representing the sedative drug names and classes, disease stage, and study
designs.
Selection criteria
We included randomised controlled trials (RCTs), quasi-RCTs, non-RCTs, and observational studies (e.g. before-and-after, interrupted-
time-series) with quantitative outcomes. We excluded studies with only qualitative outcomes or that had no comparison (i.e. no control
group or no within-group comparison) (e.g. single arm case series).
Data collection and analysis
Two review authors independently screened titles and abstracts of citations, and full text of potentially eligible studies. Two review
authors independently carried out data extraction using standard data extraction forms. A third review author acted as arbiter for
both stages. We carried out no meta-analyses due to insufficient data for pooling on any outcome; therefore, we reported outcomes
narratively.
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Main results
The searches resulted in 14 included studies, involving 4167 adults, of whom 1137 received palliative sedation. More than 95% of
people had cancer. No studies were randomised or quasi-randomised. All were consecutive case series, with only three having prospective
data collection. Risk of bias was high, due to lack of randomisation. No studies measured quality of life or participant well-being, which
was the primary outcome of the review. Five studies measured symptom control, using four different methods, so pooling was not
possible. The results demonstrated that despite sedation, delirium and dyspnoea were still troublesome symptoms in these people in the
last few days of life. Control of other symptoms appeared to be similar in sedated and non-sedated people. Only one study measured
unintended adverse effects of sedative drugs and found no major events; however, four of 70 participants appeared to have drug-induced
delirium. The study noticed no respiratory suppression. Thirteen of the 14 studies measured survival time from admission or referral
to death, and all demonstrated no statistically significant difference between sedated and non-sedated groups.
Authors’ conclusions
There was insufficient evidence about the efficacy of palliative sedation in terms of a person’s quality of life or symptom control.
There was evidence that palliative sedation did not hasten death, which has been a concern of physicians and families in prescribing
this treatment. However, this evidence comes from low quality studies, so should be interpreted with caution. Further studies that
specifically measure the efficacy and quality of life in sedated people, compared with non-sedated people, and quantify adverse effects
are required.
P L A I N L A N G U A G E S U M M A R Y
Sedation medication for relieving symptoms at the end of life
Background
People with diseases that are not curable may have a variety of symptoms at the end of life. These symptoms can include confusion
(delirium), anxiety, restlessness, breathlessness (dyspnoea), pain, vomiting, and distress. Medicines that reduce consciousness (sedatives)
may help relieve these symptoms when people are close to death.
Treatment with sedatives can vary in terms of the level of sedation (mild, intermediate, and deep), and duration (intermittent or
continuous).
Study chara cteristics
We searched international databases in October 2012 and again in December 2014 for studies of terminally ill adults who required
sedation in order to control symptoms. We found 14 studies of around 4000 people. The studies compared sedation versus non-
sedation. Most people in the studies had cancer (95%). The studies took place in hospices, palliative care units, hospitals, and the
home.
Key results
Five studies showed that sedatives did not fully relieve delirium or breathlessness. There was no difference between the groups in terms
of the other symptoms. There was no difference in time from admission or referral to death
Only one study reported side effects, and did not report any major problems.
Future studies should focus on how sedatives affect a person’s quality of life, or peacefulness and comfort during the dying phase, and
how well sedation controls the distressing symptoms. Side effects should be better reported.
Quality of evidence
The studies were not randomised controlled trials (where people are randomly allocated to one of two or more treatment groups), and
so we judged the quality of the evidence as poor.
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B A C K G R O U N D
Description of the condition
Terminally ill people experience a variety of symptoms in the last
hours anddays of life, includingdelirium, agitation, anxiety, termi-
nal restlessness, dyspnoea, pain, vomiting, and psychological and
physical distress. Terminal restlessness is an agitated delirium that
occurs in some people during the last few days of life (Doyle 2008).
The Study toUnderstandPrognoses andPreferences forOutcomes
and Risks of Treatments (SUPPORT) indicated that during their
last three days of life, 80% of dying hospitalised people had se-
vere fatigue, 50% severe dyspnoea, and 40% severe pain (Lynn
1997). In another study, the most commonly reported symptoms
were fatigue, dyspnoea, and dry mouth, with the most distressing
being fatigue, dyspnoea, and pain (Hickman 2001). Other dis-
tressing symptoms reported in this and other similar studies were
noisy breathing, excess respiratory secretions, agitation, anxiety,
constipation, nausea and vomiting, anorexia, incontinence, pres-
sure sores, and insomnia (e.g. Cowan 2006; Morita 2005).
In the terminal phase of life (i.e. when the disease is progressive,
far advanced, incurable, and death is imminent), these symptoms
may become refractory, unable to be controlled by supportive and
palliative therapies specifically targeted to these symptoms. Pallia-
tive sedation therapy is one potential solution to providing relief
from these refractory symptoms.
Description of the intervention
Palliative sedation therapy has been described as “the use of seda-
tive medications to relieve intolerable suffering from refractory
symptoms by a reduction in patient consciousness” (De Graeff
2007). The therapy can vary in terms of level of sedation (mild, in-
termediate, and deep), and duration (intermittent or continuous).
Sedation can be achieved by drugs that are primarily sedatives, and
are not designed to treat the underlying condition or symptom,
or by drugs that have some effect on the underlying symptom and
have a secondary effect of causing somnolence.
Drug classes used for palliative sedation include benzodiazepines
(particularlymidazolamand clonazepam), antipsychotics, opioids,
and hypnotics. They may be administered intravenously or sub-
cutaneously.
How the intervention might work
Sedation in terminally ill people in the last hours or days of life
is intended to provide relief from refractory symptoms that are
not controlled by other methods. Sedative drugs such as benzodi-
azepines are titrated to achieve the desired level of sedation, and
potentially the desired level of symptom control; the level of seda-
tion can be easily maintained and the effect is reversible. There-
fore, sedation may be useful in terminally ill people where symp-
tom control cannot be achieved by drugs targeted at the specific
symptom. There is also some concern as to whether this form of
treatment may shorten life, and could be used to hasten death
intentionally, similarly to euthanasia, so assessing the effects on
survival is important.
Why it is important to do this review
There are existingCochrane reviews on interventions for particular
symptoms (e.g. interventions for noisy breathing in people near
to death (Wee 2008), opioids for palliation of breathlessness (
Jennings 2001), drug therapy for delirium in terminally ill people
(Jackson 2004a), benzodiazepines and related drugs for insomnia
in palliative care (Hirst 2009), and anxiety in palliative care (
Jackson 2004b)), and one systematic review of one drug (propofol)
for terminal sedation (McWilliams 2010). One systematic review
was published after the commencement of this review (Maltoni
2012a), which reports on most of the studies included in this
review. The focus of the review was survival. Our review aimed to
bring together in one place the limited information on all drugs
used to sedate terminally ill people, for all symptoms, specifically
in the terminal phase of life, as distinct from the broader palliative
care setting.
O B J E C T I V E S
To assess the evidence for the benefit of palliative pharmacological
sedation on quality of life, survival and specific refractory symp-
toms in terminally ill adults during their last few days of life.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), quasi-RCTs, non-RCTs,
and observational studies (e.g. before-and-after, interrupted-time-
series) with quantitative outcomes. We made this choice because
we knew prior to starting the review that there would be few, if
any, RCTs in this area. We excluded studies with only qualitative
outcomes or that had no comparison (i.e. no control group or no
within-group comparison) (e.g. single arm case series).
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Types of participants
We included studies of terminally ill adults (aged 15 years or
greater) who required sedation in order to control symptom(s)
(e.g. agitation, anxiety, insomnia, terminal restlessness, dyspnoea,
and pain). We considered all terminal conditions (malignant and
non-malignant), in all settings (e.g. home, hospital, and palliative
care institution).
Types of interventions
Any medication with a sedative effect (e.g. benzodiazepines, bar-
biturates, anaesthesia, opioids, antipsychotics, antihistamines, or
other hypnotics) where the intention was sedation for symptom
relief. Sedation may have been given continuously or intermit-
tently, with the intention of reducing the level of consciousness
to relieve symptoms. Sedation may have been deep (unconscious)
or the person may have had periods when they were drowsy, but
not unconscious. The comparator was no sedation. Sedative med-
ications may have been given in very low doses (e.g. for sleep at
night), but the intention was not to sedate to relieve intractable
symptoms.
Types of outcome measures
Primary outcomes
1. Quality of life or a person’s well-being. This would usually
be measured by a proxy (e.g. doctor, nurse, carer), but in certain
circumstances may have been measured by the person during
periods of adequate consciousness. We used the term ’quality of
life’ to represent any domain related to the quality of the person’s
experience during the dying phase. This may have included
peacefulness or comfort, carer’s satisfaction with the person’s
experience, or a multi-dimensional assessment of symptom
control affecting quality of life, for example.
Secondary outcomes
1. Control of specific symptom(s) (e.g. agitation, anxiety,
insomnia, terminal restlessness, dyspnoea, and pain).
2. Duration of symptom control.
3. Time to control of symptoms.
4. Adverse effects of treatment. For example, for antipsychotics
these may include: worse drowsiness than intended,
extrapyramidal effects, akathisia (restlessness), antipsychotic
malignant syndrome, urinary retention, and constipation; and
for benzodiazepines: drowsiness, ataxia, confusion, falls,
increased restlessness, respiratory depression, and hypotension.
5. Duration of institutional care.
6. Time to death.
7. Carer satisfaction.
Search methods for identification of studies
Electronic searches
We searched the following databases:
1. the Cochrane Central Register of Controlled Trials
(CENTRAL; 2014, Issue 11);
2. MEDLINE (Ovid) (1946 to November 2014);
3. EMBASE (Ovid) (1974 to December 2014).
Appendix 1 shows the search strategies. We applied no language
or date restrictions.
We also searched clinical trials registries (ClinicalTrials.gov; the
World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP) (apps.who.int/trialsearch/)) in Octo-
ber 2012 and again in December 2014 to find any ongoing trials
or to locate other publications that might not have been found in
the database searches.
Searching other resources
1. Reference lists of relevant textbooks, review articles, and
relevant studies.
2. We wrote to investigators known to be involved in previous
studies, seeking information about unpublished or incomplete
trials.
Data collection and analysis
Selection of studies
We used the search strategy described to obtain titles and abstracts
of studies that may be relevant to the review. Two review authors
(EB, MvD) independently screened the titles and abstracts, and
discarded studies that were not applicable; however, we initially
retained studies and reviews thatmight have included relevant data
or information on studies.
Two review authors (EB, MvD) independently assessed the re-
trieved full-text of these studies to determine which studies sat-
isfied the inclusion criteria. A third review author was to act as
arbiter if needed (GM).
Data extraction and management
Two review authors (LM, ST) independently carried out data ex-
traction using standard data extraction forms. We translated stud-
ies reported in non-English language journals before assessment.
Wheremore thanone publicationof one study existed,we grouped
reports together and we used the publication with the most com-
plete data in the analyses. Where relevant outcomes were only
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published in earlier versions, we used these data as well. We high-
lighted any discrepancy between published versions. A third re-
view author (EB) acted as arbiter. One review author (EB) used
Review Manager 5 software to enter data, which we would have
used to perform meta-analyses (RevMan 2014).
Assessment of risk of bias in included studies
For RCTs, two review authors (LM, ST) independently assessed
the following items using the Cochrane ’Risk of bias’ assessment
tool (Higgins 2011). A third review author (EB) acted as arbiter.
1. Adequate sequence generation (selection bias).
2. Allocation concealment (selection bias).
3. Blinding of participants and personnel.
4. Blinding of outcome assessment (detection bias).
5. Incomplete outcome data (attrition bias).
6. Selective reporting (reporting bias).
7. Other bias.
For non-randomised, comparative trials, the first and second cri-
teria were set to ’high risk of bias’. We included two additional
criteria to assess selection bias in non-randomised studies:
1. were baseline characteristics similar?
2. were baseline outcome measurements similar?
This follows the recommendations of theCochrane Effective Prac-
tice and Organisation of Care (EPOC) review group for assess-
ing risk of bias in non-randomised studies. For future updates of
this review, we plan to use the Cochrane ACROBAT-NRSi tool
(Sterne 2014).
We assessed each of these criteria as low risk of bias, unclear risk
of bias, or high risk of bias.
Measures of treatment effect
Primary outcomes
Quality of life or a person’s well-being
We anticipated that studies would measure quality of life or a per-
son’s well-being on a recognised quality of life continuous scale.
Since there are many quality of life scales, we planned to use the
standardised mean difference (SMD) (with standard deviation)
between the intervention and control groups to include all com-
parative studies with a quality of life scale or well-being scale as
outcome. However, no included studies measured the primary
outcome.
Secondary outcomes
Symptom control
Where studies reported symptom control on a continuous scale,
we planned to use SMD (with 95% confidence interval (CI)) to
combine them in a similar method to the primary outcome.
Where studies reported symptom control on a dichotomous scale
(e.g. relief versus no relief ), we planned to combine these studies
using risk ratio (RR) in the intervention group compared with
control (with 95% CI).
If data were reported using a short ordinal scale (e.g. no relief,
some relief, moderate relief, good relief ), we planned to combine
the moderate and good relief categories, and the none and mild
categories and include these with the dichotomous outcome stud-
ies.
Adverse effects of treatment
Weplanned to use the proportion of participants experiencing any
adverse effect of treatment, and combine studies using RR (and
95% CI).
Duration of symptom control, time to control of symptoms,
duration of institutional care, and time to death
If there had been sufficient studies to meta-analyse duration of
symptom control, time to control of symptoms, duration of insti-
tutional care, and time to death, we intended to use the generic
inverse variance method to pool hazard ratios (Higgins 2011).
Carer satisfaction
We planned to pool studies where carer satisfaction was reported
on a continuous scale by calculating the standardised mean differ-
ence (SMD) with standard deviation (SD).
Unit of analysis issues
We thought it unlikely that any studies would utilise a cluster or
cross-over design, so the unit of randomisation or allocation would
have been the individual participant.
Dealing with missing data
If necessary we requested any further information from the study
authors by written correspondence (e.g. emailing or writing (or
both) to corresponding author(s)), however no additional relevant
information was included in the review. We planned to perform
a careful evaluation of important numerical data such as numbers
of participants screened; numbers of randomised participants; and
number of participants in the intention-to-treat (ITT), as-treated,
and per-protocol (PP) populations; however, there were no ran-
domised or quasi-randomised studies. We investigated attrition
rates, for example drop-outs, losses to follow-up, and withdrawals.
We planned to appraise issues of missing data and imputation
methods (e.g. last-observation-carried-forward (LOCF)) critically
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(Higgins 2011); however, the level of reporting within studies was
generally insufficient for us to assess this.
Assessment of reporting biases
We assessed the potential for publication bias by checking clinical
trials registers for unpublished studies. If we had found more than
20 studies, we intended to use the funnel plot statistic and funnel
plots to assess for the potential existence of small study bias (
Higgins 2011).
Data synthesis
We planned to pool data using the random-effects model as we
expected heterogeneity of treatments and participants, but we also
planned to use the fixed-effect model to evaluate robustness of the
model chosen and susceptibility to outliers.
Subgroup analysis and investigation of heterogeneity
We planned to undertake subgroup analyses according to:
1. the condition causing the need for palliative care (i.e.
malignant versus non-malignant);
2. drug class; and
3. main symptom being treated.
There were insufficient studies to permit any of these subgroup
analyses.
We planned to assess heterogeneity using the I2 statistic, and make
a decision to either:
1. combine studies using a random-effects model (where the I
2 statistic was low to moderate, and the studies appeared to be
reasonably similar); or
2. not combine all studies (where either the I2 statistic was
moderate and reasons for heterogeneity were plausible and,
therefore, indicated that combining studies was not appropriate,
or the I2 statistic was high).
When combining studies, we intended to undertake post hoc sub-
group analyses if sufficient studies existed in each subgroup of the
plausible heterogeneity factor.
In investigating heterogeneity of the included studies, we planned
to consider treatment factors such as the continuation or weaning
of sedation, degree of sedation achieved, timing and dosage of
medication, and study design factors such as the length of follow-
up, type of proxy used for quality of life measurement, and time
of outcome measurement.
Sensitivity analysis
Since we planned to include included quasi-randomised and non-
randomised comparative studies, we planned to investigate the ef-
fect of omitting such studies on the results using sensitivity anal-
ysis.
R E S U L T S
Description of studies
Results of the search
The searches resulted in 6685 citations to screen. After title and
abstract screening, we reviewed 70 full-text articles, resulting in
14 included studies and three awaiting classification (see Figure
1). We found no unpublished studies from clinical trials registers.
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Figure 1. Study flow diagram.
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Included studies
See: Characteristics of included studies table.
We included 14 comparative studies (Alonso-Babarro 2010; Bulli
2007; Caraceni 2012; Chiu 2001; Fainsinger 1998; Kohara
2005; Maltoni 2009; Maltoni 2012b; Muller-Busch 2003; Radha
Krishna 2012; Rietjens 2008; Stone 1997; Sykes 2003; Vitetta
2005). All studies compared a group of people who received pal-
liative sedation with a concurrent control group who did not re-
ceive sedation. All were consecutive case series, however only four
had prospective data collection (Bulli 2007; Chiu 2001; Maltoni
2009;Maltoni 2012b). One of these three used matching to select
the controls (Maltoni 2009). The other 10 studies were retrospec-
tive chart reviews. None was randomised or quasi-randomised.
The 14 studies included 4167 adults, of whom 1137 received pal-
liative sedation. The proportion of people in each study receiving
palliative sedation ranged from 12% to 67%. In all studies, the
proportionof peoplewith a cancer diagnosiswas greater than95%.
The setting of the studies was hospices (seven studies), palliative
care units (five studies), hospital oncology wards (three studies),
and home-based palliative care (two studies). Three studies in-
volvedmore than one setting; Bulli 2007 was set in both the home
and hospice, Chiu 2001 in hospice and palliative care units, and
Stone 1997 in a hospital ward and a hospice.
The most commonly used drug to achieve palliative sedation
was midazolam, which all 14 studies used. Other drugs were
haloperidol (eight studies) and chlorpromazine (five studies). A
small proportion of people received only opioids (morphine, fen-
tanyl, and methadone), or propofol, other benzodiazepines (lo-
razepam, diazepam, clonazepam, flunitrazepam, and levomepro-
mazine/methotrimeprazine), antihistamines (promethazine and
chlorphenamine), phenobarbital, scopolamine hydrobromide, or
ketamine hydrochloride.
The mean duration of sedation from initiation to death ranged
from 19 hours (Rietjens 2008) to 3.4 days (Kohara 2005) in the
nine studies that reported duration of sedation, although the Sykes
2003 study had a small group of people who received palliative
sedation for seven days prior to death in addition to their larger
group who received sedation in the last 48 hours of life.
The 14 comparative studies had control groups of concurrent
participants in the same care setting who did not receive pallia-
tive sedation. Only the study by Maltoni matched control partic-
ipants for age group, gender, reason for hospice admission, and
Karnofsky performance status (Maltoni 2009). Four studies stated
a funding source being their institution or a government granting
body (Alonso-Babarro 2010; Caraceni 2012; Chiu 2001; Maltoni
2009), and three studies stated that there were no competing in-
terests to declare (Maltoni 2012b; Muller-Busch 2003; Rietjens
2008).
The following table describes the included studies.
Study Setting Study
design
Number
(%) in seda-
tion group
Num-
ber in non-
sedated
group
Two
most com-
mon indi-
cations for
sedation
Most com-
mon seda-
tive(s) used
Type of se-
da-
tion at com-
mencement
Mean dura-
tion of se-
dation
Alonso-
Babarro
2010
Home-
based care
team
Retrospec-
tive cohort
of consecu-
tive cases
29 (12%) 236 Delirium
(62%), dys-
pnoea
(14%)
Midazolam,
levomepro-
mazine
Dose titra-
tion to ef-
fective con-
trol of symp-
toms
2.6 days
(range 1-10
days)
Bulli 2007 4 hospice
and home-
based teams
Prospec-
tive cohort
of consecu-
tive cases
136 (13%) 939 Not
reported
Benzodi-
azepines,
opioids, an-
tipsychotics
Continu-
ous, deep
68% ≤ 1
day,
25% 2-4
days,
6% 5-10
days
Caraceni
2012
Palliative
care team in
tertiary care
cancer hos-
Retrospec-
tive cohort
of consecu-
tive cases
83 (64%) 46 Dysp-
noea (37%),
delirium
Benzodi-
azepine
(48%), an-
Not
reported
Median 18
hours
8Palliative pharmacological sedation for terminally ill adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
pital (31%) tipsychotic
(45%), an-
tipsychotic
plus benzo-
diazepine
(26%)
Chiu 2001 Hospice and
Palliative
care unit
Prospec-
tive cohort
of consecu-
tive cases
70 (25%) 206 Delirium
(57%), dys-
pnoea
(23%)
Haloperidol
(50%)
, midazolam
(24%)
Intermit-
tent (63%)
, continuous
(37%)
Median
5 days
Fainsinger
1998
Hospice Retrospec-
tive cohort
of consecu-
tive cases
23 (29%) 53 Delirium
(87%), dys-
pnoea (4%)
Midazo-
lam (91%),
chlorpro-
mazine and
lorazepam
(9%)
Contin-
uous (61%),
intermittent
(30%)
2.5 days
(Median
1 day)
Kohara
2005
Palliative
care unit
Retrospec-
tive cohort
of consecu-
tive cases
63 (51%) 61 Dysp-
noea (63%),
malaise/
restlessness
(40%)
Midazo-
lam (98%)
, haloperidol
(84%)
Contin-
uous (69%),
intermittent
(30%)
3.4 days
Maltoni
2009
4 hospices Prospective
matched co-
hort
267 251 Uncon-
trolled
symptoms
(53%), ter-
minal phase
of life (41%)
Lorazepam
(38%),
chlorpro-
mazine
(38%)
Contin-
uous (44%),
intermittent
(56%), deep
(38%), mild
(62%)
4 days (SD
6)
(Median 2
days)
Maltoni
2012b
2 palliative
care units
Prospec-
tive cohort
of consecu-
tive cases
72 (22%) 255 Delirium
(61%), exis-
tential dis-
tress (38%)
Benzodi-
azepines
(76%), an-
tipsychotics
(38%)
Contin-
uous (92%),
intermittent
(6%)
32.2
hours (range
25-253)
Muller-
Busch 2003
Palliative
care unit
Retrospec-
tive cohort
of consecu-
tive cases
80 (15%) 468 Pain (38%),
dyspnoea
(23%)
Midazolam Titrated
to symptom
con-
trol, then in-
termittent
if possible to
control
symptoms
Approx. 60
hours
Radha
Krishna
Oncol-
ogy ward in
Retrospec-
tive cohort
68 (29%) 170 Anxiety
(24%), dys-
Midazolam,
haloperidol
Titrated
to symptom
Not
reported
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(Continued)
2012 tertiary care
hospital
of consecu-
tive cases
pnoea
(21%)
control
Rietjens
2008
Acute pallia-
tive care unit
Retrospec-
tive cohort
of consecu-
tive cases
68 (43%) 89 Termi-
nal restless-
ness (62%),
dyspnoea
(47%)
Midazo-
lam (75%),
propofol
(15%)
Not
reported
Median 19
hours
Stone 1997 Hospi-
tal support
team and
hospice
Retrospec-
tive cohort
of consecu-
tive cases
30 (26%) 85 Delir-
ium (60%)
, mental an-
guish (27%)
Midazo-
lam (80%)
, haloperidol
(37%)
Not
reported
1.3 days
Sykes 2003 Hospice Retrospec-
tive cohort
of consecu-
tive cases
80 (34%) 157 Not
reported
Midazolam,
methotri-
meprazine
Not
reported
Not
reported
Vitetta 2005 Hospice Retrospec-
tive cohort
of consecu-
tive cases
68 (67%) 34 Not
reported
Benzodi-
azepines,
haloperidol
Titrated
to symptom
con-
trol, then in-
termittent
Not
reported
SD: standard deviation.
Excluded studies
See: Characteristics of excluded studies table.
We found 11 studies that described the use of palliative sedation in
case series of people, but they made no comparison with a control
group.
Risk of bias in included studies
See Figure 2 and Figure 3 for ’Risk of bias’ summary graphs.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All 14 studies were at high risk of selection bias, as none was
randomised or quasi-randomised.
Blinding
No studies allocated people to treatment group; blinding of treat-
ment was not possible; and blinded assessment of outcomes was
not carried out; however, the main outcome assessed in the stud-
ies was survival, which is an objective measure. Therefore, they
are all at high risk of performance bias, but low risk of detection
bias. One study reported satisfaction with treatment, with people
responding to the questionnaire being aware of treatment group,
therefore, this study was at high risk of bias for satisfaction with
treatment (Chiu 2001). Five studies assessed symptom control,
and were at high risk of bias for the outcome symptom control .
Incomplete outcome data
All studies were consecutive case series. Studies did not generally
report on the proportion of missing data for outcomes. One study
reported that 9% of survival time data were missing (Chiu 2001).
Selective reporting
It is unlikely that any of the outcomes of this review weremeasured
but not reported.
Other potential sources of bias
Since these were all non-randomised studies, we assessed two fur-
ther areas for risk of bias. Six studies reported on the difference be-
tween the sedated and non-sedated groups on baseline characteris-
tics (Alonso-Babarro 2010; Bulli 2007; Fainsinger 1998; Maltoni
2009; Muller-Busch 2003; Rietjens 2008). The five unmatched
studies reported significant differences between the groups, so are
at high risk of bias in comparing the outcomes between the groups.
WhilstMaltoni 2009matchedparticipants on several factors, there
was a significant difference between the groups in symptoms at ad-
mission, with the sedated group having more uncontrolled symp-
toms, as expected. Therefore, this study was also at high risk of
bias. The other eight studies did not report a comparison of groups
at baseline, so were at unclear risk of bias.
We also assessed whether the groups were alike at baseline on
the outcomes to be measured in the study. Since survival is not
an outcome that can be measured at baseline, all studies were at
unclear risk of bias for survival. Only five studies measured an
outcome other than survival.
Effects of interventions
Primary outcomes
No studies measured quality of life or well-being.
Secondary outcomes
Five studies reported on symptom control (Caraceni 2012; Chiu
2001; Fainsinger 1998; Muller-Busch 2003; Rietjens 2008). One
study reported symptom control as odds ratios for prevalence of
each symptom in the last seven days of life (Caraceni 2012); one as
mean scores (Chiu 2001); one as adequacy of control rated good,
fair, or poor (Fainsinger 1998); and two as symptom prevalence
(Muller-Busch 2003; Rietjens 2008). Therefore, we were unable
to pool results for this outcome.
Caraceni 2012 reported only the odds ratio for comparison of
sedated and non-sedated groups for the prevalence of symptoms
during the seven days before death, but did not report the counts
or percentages that these were based on. CIs around the odds
ratios were wide. There was no statistically significant difference
between the sedated and non-sedated groups in the prevalence
of confusion, gastrointestinal symptoms, pain, or psychological
distress. The odds ratio for recurrent agitationwas 3.5 (95%CI 1.4
to 8.8), for recurrent drowsiness was 0.3 (95% CI 0.2 to 0.7), and
for recurrent dyspnoeawas 4.2 (95%CI 1.9 to 9.2), indicating that
the sedated groupwasmore likely to experience recurrent agitation
and dyspnoea, but less likely to experience recurrent drowsiness
than the non-sedated group.
Chiu 2001 measured pain, dyspnoea, and delirium in 70 people
in the sedated group and 206 people in the non-sedated group,
and found that pain scores and dyspnoea scores measured two
days before death were similar between groups. The mean score
for pain (10-point scale) was 2.5 in the sedated group and 2.1 in
the non-sedated group (P value = 0.27, t-test). The mean score for
dyspnoea (10-point scale) was 3.0 in the sedated group and 2.9
in the non-sedated group (P value = 0.78, t-test). However, mean
delirium score two days before death was significantly worse in the
sedated group (1.8 in the sedated group compared with 1.1 in the
non-sedated group, 0 to 3 scale, P value < 0.001, t-test).
Fainsinger 1998 measured adequacy of overall symptom control as
good, fair, or poor, daily for the day of death and six days prior in
23 people in the sedated group and 53 people in the non-sedated
group. Symptom control was significantly worse in the sedated
group on the day of death and the two days prior (P value < 0.001).
The percentage of people in the sedated group with good control
was 61% on the day of death, 35% on the day prior, and 38% two
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days prior, compared with 96% on the day of death, 88% on the
day prior, and 87% two days prior in the non-sedated group.
Muller-Busch 2003 measured prevalence of pain, dyspnoea, delir-
ium, and anxiety over the course of admission, and during the last
48 hours of life. They did not report between-group results, but
rather the change over time in each group for each symptom. Pain
improved significantly in both groups between admission and the
last 48 hours of life; however, all other symptoms worsened sig-
nificantly.
Rietjens 2008measured symptomprevalence at 0 to 24hours prior
to death, and 25 to 48 hours prior to death. Only participants
commencing sedation during this period were reported for the
sedated group (45 for the 0 to 24 hours period, and 13 for the 25
to 48 hours period). That is, it was a measure of symptom control
shortly after commencing sedation. Pain, constipation, nausea/
vomiting, and anxiety were not significantly different between the
sedated and non-sedated groups. However, in both periods, the
percentage of people with dyspnoea was significantly higher in the
sedated group at 50% of people compared with 31% in the non-
sedated group at 0 to 24 hours prior to death, and 69% in the
sedated group compared with 38% in the non-sedated group 25
to 48 hours prior death. The percentage of people with delirium
at 0 to 24 hours prior to death was also significantly worse in the
sedated group (29% in the sedated group compared with 13% in
the non-sedated group), but not at 25 to 48 hours (31% in the
sedated group compared with 23% in the non-sedated group).
No studies measured duration of symptom control or time to
control of symptoms in using comparative methods.
Only one study reported on unintended adverse effects of seda-
tion (Chiu 2001). It stated that there were no significant adverse
events in the sedated group; however, four of 70 (6%) participants
appeared to have drug-induced delirium. It was also reported that
no respiratory suppression was noted.
The least biased time comparison possible between intervention
and control groups was from admission/referral to death in this set
of observational studies. Whilst all studies except one measured
time from admission or referral to death, some used mean time,
and some used median time.Measures of variance were frequently
missing or indicated skewed data distributions; therefore, we were
unable to pool results. We have reported these results in tabular
form below.
Table: survival time comparison between sedated and
non-sedated groups, from time of admission or
referral
Study Measurement unit Survival time in the se-
dated group
Survival time in the non-
sedated group
Comparison
Alonso-Babarro 2010 Mean 64 days (SD 60) 63 days (SD 88) P value = 0.963, t-test
Bulli 2007
(cohort 1)
Median 23 days 23 days NS, test not reported
Bulli 2007
(cohort 2)
Median 24 days 17 days -
Chiu 2001 Mean 28.5 days 24.7 days P value = 0.43, t-test
Fainsinger 1998 Mean 9 days (SD 5) 6 days (SD 7) P value = 0.09, t-test
Kohara 2005 Mean 28.9 days (SD 25.8) 39.5 days (SD 43.7) P value = 0.10, t-test
Maltoni 2009 Median 12 days 9 days P value = 0.95, log-rank
test
HR 0.92
(90% CI 0.80 to 1.06)
Maltoni 2012b Mean 11 days (95% CI 9 to 11) 9 days (95% CI 7 to 11) P value = 0.51, log-rank
test
Muller-Busch 2003 Mean 21.5 days (SD 20.3) 21.1 days (SD 23.6) NS, t-test
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(Continued)
Radha Krishna 2012 Median 8 days (approx.)* 8 days (approx.)* P value = 0.78, log-rank
test
Rietjens 2008 Median 8 days 7 days P value = 0.12, test not re-
ported
Stone 1997 Mean 18.6 days 19.1 days P value > 0.2, test not re-
ported
Sykes 2003 Mean 14.3 days (95% CI 11.2 to
17.4)1
36.6 days (95% CI 31.5 to
41.7)2
14.2 days (95% CI 12.7 to
15.7)
P value = 0.23, t-test
P value < 0.001, t-test
Vitetta 2005 Mean 36.5 days (SD 66) 17.0 days (SD 43) P value = 0.12, t-test
CI: confidence interval; HR: hazard ratio; NS: not statistically significantly different; SD: standard deviation
* Times not reported; have been interpolated from survival curves
1 people receiving palliative sedation for last 48 hours of life
2 people receiving palliative sedation for last 7 days of life
1 study gave results for the outcome of satisfaction with treatment, as reported by the medical staff, family, and participant (Chiu
2001). For the medical staff, satisfaction was rated as 71% yes, 20% fair, 9% no, 0% unavailable. For the family, satisfaction was
rated as 67% yes, 20% fair, 4% no, 9% unavailable. For the participant, satisfaction was rated as 53% yes, 10% fair, 4% no, 33%
unavailable
D I S C U S S I O N
Summary of main results
No studies reported on the primary outcome of this review (i.e.
quality of life or well-being).
Four studies compared the sedated and non-sedated groups for
control of symptoms, and showed that despite sedation with the
intent to control symptoms, delirium and dyspnoea were still trou-
blesome symptoms in these people in the last few days of life,
and were significantly worse in the sedated group. Control of
other symptoms appeared to be similar in sedated and non-sedated
groups.
All studies except one compared survival time in the sedated and
non-sedated groups, and concluded that there was no statistically
significant difference between the groups. This is important, as
there has been extensive discussion in the literature about whether
palliative sedation might shorten life, therefore leading to uncer-
tainty by some physicians about whether to use this treatment
for fear of the perception that they were performing a form of
euthanasia (Billings 1996; De Graeff 2007; Rietjens 2006). The
use of time from admission to death in comparative groups may
be a weak measure of any potential effect of palliative sedation
on shortening life. However, it is difficult to determine what the
comparison would be in the group who did not receive sedation,
and time from admission to death may be the only feasible com-
parative measure. Although we were unable to meta-analyse this
outcome, and CIs around the point estimates in individual studies
were wide, there was consistency in this result over all studies, with
12 of the 13 studies having a longer survival time in the sedated
group.
Overall completeness and applicability of
evidence
No studies measured the primary outcome of this review, quality
of life or well-being, in a formal way. Many of the study reports
discussed the ’settling’ of symptoms in an anecdotal way; however,
there were no quantitative reports.
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Quality of the evidence
There were no randomised or quasi-randomised trials, and it is
unlikely that these will be done. Therefore, the best quality evi-
dence will come from well-designed observational studies. Only
one study in this review attempted to reduce selection bias be-
tween the groups by matching groups on baseline characteristics
(Maltoni 2009). However, it is likely that even if this is done, the
groups will differ significantly in their level of symptom control,
with people with more severe symptomsmore likely to receive pal-
liative sedation. Hence, even matching of controls cannot adjust
for this confounder. It would be possible to adjust for this con-
founder (and others) statistically, but this was not done in any of
the reported studies.
Potential biases in the review process
The search strategy for this review was wide; however, this was a
difficult topic to search. It was possible that the searchmissed some
studies, despite screening more than 5000 citations and screening
the bibliographies of narrative reviews.
Agreements and disagreements with other
studies or reviews
This is the first review, to our knowledge, that attempts to sum-
marise only studies that have compared outcomes for sedated and
non-sedated people.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Although there is no evidence from randomised controlled trials
(RCTs) and limited evidence from observational studies about the
efficacy of palliative sedation in terms of a person’s quality of life
or symptom control, compared with non-sedated people, there
was evidence that palliative sedation does not hasten death, which
has been a concern of physicians and families in prescribing this
treatment. However, this evidence comes from low quality studies,
so should be interpreted with caution.
Implications for research
Measurement
Studies that specifically measure the efficacy of sedation in terms
of a person’s well-being and control of symptoms, compared with
non-sedated people, are required. This therapy is widely used, in
both continuous deep sedation and intermittent forms, but ev-
idence is lacking on the success of controlling symptoms ade-
quately. Adverse events reporting also needs to be improved in or-
der to quantify the potential harms of treatment. Description of
the depth of sedation, timing, and length of sedation was poorly
reported in many studies, and the method of measuring and de-
scribing this was inconsistent between studies.
Design
Future studies should attempt to utilise control groups that are
close in prognostic factors to the intervention group, in order to
make the groups as alike as possible, except for the presence of
sedation. Alternatively, statistical methods to adjust for differences
between intervention and control groups could be used.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alonso-Babarro 2010
Methods Design: retrospective medical record review of a consecutive case series for calendar years
2002-2004, comparing people who received palliative sedation with people who did not
Setting: home-based care by palliative care team in Madrid, Spain
Participants 245 people with cancer who died at home. 29 (12%) received palliative sedation. Indi-
cations for sedation were delirium (62%), dyspnoea (14%), nausea/vomiting/bowel ob-
struction (7%), seizures (7%), anxiety/psychoexistential suffering (7%), and pain (3%)
Interventions Palliative sedation treatment was according to a written protocol, using midazolam, then
levomepromazine if midazolam not effective, then phenobarbital if levomepromazine
not effective. Mean duration of sedation was 2.6 days (range 1-10). Mean dose in the
last 24 hours of life was midazolam 73.88 mg and levomepromazine 125 mg. Only 2
people received levomepromazine, and 0 required phenobarbital
Outcomes Survival after start of palliative care team care. Mean of 63.9 days (SD 60.0) in sedation
group and 63.3 days (SD 88.1) in non-sedation group
Notes Funding source: NIH grants (Alonso-Babarro, Torres-Vigil)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No randomisation or other allocation to
treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of treatment group possible
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not done. Retrospective chart review.
However, survival was an objective out-
come
Incomplete outcome data (attrition bias)
All outcomes
Low risk All included participants’ data reported
Selective reporting (reporting bias) Low risk No evidence of outcomes being measured
but not reported
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Alonso-Babarro 2010 (Continued)
Similarity of baseline characteristics High risk Baseline differences in age (sedated group
was younger), and awareness of prognosis
(sedated group was more aware)
Similarity of outcomes at baseline Unclear risk Baseline comparison of the only outcome
of this review that was reported was not
possible (survival)
Bulli 2007
Methods Design: prospective consecutive case series in 2000 and 2003-2004, comparing people
who received palliative sedation with people who did not
Setting: 4 home and hospice-based palliative care teams in Florence, Italy
Participants 1075 people; 1045 had cancer. 136 (13%) received palliative sedation. Indications for
sedation were not reported. Baseline quality of life (Edmonton Symptom Assessment
System questionnaire) was not statistically significantly different between the sedated
and non-sedated groups, although slightly lower in the sedated group
Interventions Treatment was at the team’s discretion. 12% received opioids only (morphine, fentanyl,
methadone), 16% combined opioids plus antipsychotics (haloperidol, chlorpromazine)
, 18% opioids plus benzodiazepines (midazolam, diazepam), and 54% opioids plus
antipsychotics plus benzodiazepines. 68% received sedation for ≤ 1 day, 25% for 2-4
days, and 6% for 5-10 days
Outcomes Survival from time of start of palliative care team intervention. Median survival times in
the sedated groups were 23 days (2000 cohort) and 24 days (2003-2004 cohort). Median
survival times in the non-sedated groups were 23 days (2000 cohort) and 17 days (2003-
2004 cohort). Reported no other outcomes of this review
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No randomisation or other allocation to
treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of treatment group possible
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Bulli 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Treating team (aware of treatment) assessed
outcomes; however, survival is an objective
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants reported (consecutive case
series)
Selective reporting (reporting bias) Low risk No evidence of outcomes being measured
but not reported
Similarity of baseline characteristics High risk Baseline quality of life similar. Sedated
participants were statistically significantly
younger, and had worse performance status
(Karnofsky index)
Similarity of outcomes at baseline Unclear risk Baseline comparison of the only outcome
of this review that was reported was not
possible (survival)
Caraceni 2012
Methods Design: retrospective chart review of consecutive case series over a 5-year period inMilan,
Italy, comparing people who received palliative sedation with people who did not
Setting: palliative care team in a tertiary care cancer hospital
Participants 129 people with cancer. 83 (64%) received palliative sedation. Indications for sedation
were predominantly dyspnoea (37%) and delirium (31%)
Interventions Protocol for palliative sedation not reported. 40 (45%) people received an antipsychotic,
43 (48%) benzodiazepine, and 23 (26%) antipsychotic plus benzodiazepine. 7 (10%)
people received opioid-only, and a minority of people received antihistamine and com-
binations of antipsychotics and benzodiazepines
Outcomes Prevalence of symptoms in the 7 days prior to death
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No randomisation or other allocation to
treatment group
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Caraceni 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of treatment group possible
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes data collected from medical
records
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants reported (consecutive case
series)
Selective reporting (reporting bias) Low risk No evidence of outcomes being measured
but not reported
Similarity of baseline characteristics Unclear risk Baseline comparison not reported
Similarity of outcomes at baseline Unclear risk Baseline comparison not reported
Chiu 2001
Methods Design: prospective consecutive case series in 1998-1999 comparing people who received
palliative sedation with people who did not
Setting: hospice and palliative care unit in Taiwan
Participants 276 people with cancer. 70 (25%) received palliative sedation. Indications for sedation
were delirium (57%), dyspnoea (23%), pain (10%), insomnia (7%), and severe itching
(3%)
Interventions Protocol for palliative sedation not reported. 50% of people received haloperidol, 24%
midazolam, 13% rapidly increasing morphine dose, 10% other benzodiazepines, and
3% chlorpromazine. The mean survival time was 12.6 ± 19.6 days from starting sedation
to the time of death (median of 5 days)
Outcomes Survival from time of start of palliative care team intervention.Mean survival timewas 28.
5 days in sedated group and 24.7 days in non-sedated group. Satisfaction with treatment
for participant and family was reported in the sedated group only. 53% of people were
satisfied, 10% rated satisfaction as fair, 4% poor, and 33%were unable to rate satisfaction
(due to reduced level of consciousness). 67% of family rated satisfaction high, 20%
fair, 4% poor, and 9% with data unavailable. Symptom scores for pain, dyspnoea, and
delirium were compared at 2 days before death. There was no statistically significant
difference between the groups in mean score for pain and dyspnoea, but the sedated
group had significantly higher mean score for delirium (1.80 in sedated group vs. 1.14
in non-sedated group, 0-3 scale, P value < 0.001). Unintended effects of sedation were
reported as minor, with 4 people experiencing drug-induced delirium
Notes Funding source: National Taiwan University Hospital
Risk of bias
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Chiu 2001 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No randomisation or other allocation to
treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of treatment group possible
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Treating team (aware of treatment) col-
lected outcomes. Therefore, for the out-
comes of symptom control and satisfaction
with treatment, we rated this study at high
risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk 24 (9%) people had missing data for sur-
vival time.Not differential between sedated
and non-sedated groups
Selective reporting (reporting bias) Low risk No evidence of outcomes being measured
but not reported
Similarity of baseline characteristics Unclear risk Baseline comparison of most characteris-
tics of palliative sedation and non-sedated
groups not reported
Similarity of outcomes at baseline High risk Non-sedated group had significantly lower
dyspnoea and delirium symptom scores.
Baseline comparison of other outcomes not
reported
Fainsinger 1998
Methods Design: retrospective chart review of consecutive case series, comparing people who
received palliative sedation with people who did not
Setting: hospice in Cape Town, South Africa
Participants 79 people who died in the hospice; all but 3 had cancer; 76 had sufficient data for
inclusion in analyses; 23 (29%) received palliative sedation; most (96%) had cancer.
Indications for sedation were delirium (87%), dyspnoea (4%), and both delirium and
dyspnoea (4%)
Interventions Protocol for palliative sedation not reported. 61% received continuous subcutaneous
midazolam, 30% intermittent doses of benzodiazepines, and 9% chlorpromazine plus
lorazepam. “Patients were sedated on average 2.5 days before death (median 1 day; range
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Fainsinger 1998 (Continued)
4 hours-12 days).”
Outcomes Survival from time of admission to the hospice. Mean time 9 days (SD 5) in sedated
group and 6 days (SD 7) in non-sedated group. Adequacy of symptom control was
measured daily, and reported for the last 6 days of life, demonstrating significantly poorer
control of symptoms in the sedated group in the last 3 days of life. No other outcomes
of this review were reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No randomisation or other allocation to
treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of treatment group possible
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes data collected from medical
records. Survival is an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants reported (consecutive case
series)
Selective reporting (reporting bias) Low risk No evidence of outcomes being measured
but not reported
Similarity of baseline characteristics High risk Non-sedated group were significantly
older, and had higher levels of dyspnoea
and delirium
Similarity of outcomes at baseline Unclear risk Baseline comparison of outcome (survival)
not possible
Kohara 2005
Methods Design: retrospective chart review of consecutive case series in calendar year 1999, com-
paring people who received palliative sedation with people who did not
Setting: palliative care unit in Japan
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Kohara 2005 (Continued)
Participants 124 consecutive participants; 63 (51%) received palliative sedation; all had cancer. In-
dications for sedation were dyspnoea (63%), general malaise/restlessness (40%), pain
(25%), agitation (21%), and nausea and vomiting (6%). 34 (54%) people had > 1 un-
controllable symptom
Interventions Protocol for palliative sedationnot reported. In the sedated group, 98%of people received
midazolam, 84% haloperidol, 10% scopolamine hydrobromide, 5% chlorpromazine,
2% flunitrazepam, and 2% ketamine hydrochloride. Mean time from start of sedation
to death was 3.4 days
Outcomes Survival time from admission to the hospice. Mean time was 28.9 days (SD 25.8) in
sedated group and 39.5 days (SD 43.7) in non-sedated group. Mean time sedated was
3.4 days. Symptom prevalence for pain, constipation, dyspnoea, nausea/vomiting, delir-
ium, and anxiety were reported for the periods 0-24 hours before death and 25-48 hours
before death comparing sedated vs. non-sedated groups. Only data from people begin-
ning sedation during these periods were reported in the sedated group, demonstrating a
significantly higher proportion of people in the sedated group having delirium (29% in
sedated group vs. 13% in non-sedated group). No other outcomes of this review were
reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No randomisation or other allocation to
treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of treatment group possible
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes data collected from medical
records. However, survival is an objective
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants reported (consecutive case
series)
Selective reporting (reporting bias) Low risk No evidence of outcomes being measured
but not reported
Similarity of baseline characteristics Unclear risk No baseline comparison of sedated and
non-sedated groups reported
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Kohara 2005 (Continued)
Similarity of outcomes at baseline Unclear risk No baseline comparison of sedated and
non-sedated groups reported
Maltoni 2009
Methods Design: prospective, non-randomised cohort study, with matching of sedated and non-
sedated participants on gender, age group, reason for admission, and Karnofsky perfor-
mance status. On admission, if sedation was chosen for a participant, they were matched
with a recent non-sedated inpatient
Setting: 4 hospices in Emilia-Romagna, Italy from March 2005 to December 2006
Participants 518 people with cancer. 267 consecutive participants in the sedated group and 251
matched recent inpatients in the non-sedated group. Reasons for admission were uncon-
trolled symptoms (53%), terminal phase of life (41%), and psychosocial distress (6%).
Indications for palliative sedation were delirium or agitation (or both) (79%), dyspnoea
(20%), pain (11%), vomiting (5%), psychological and physical distress (19%), only psy-
chological distress (6%), and other reason (4%)
Interventions Criteria for initiating palliative sedation were standardised; however, protocol for ad-
ministering sedation not reported. Sedation was achieved with antipsychotics in 84%,
benzodiazepines in 54% and opioids in 26%. Mean duration of sedation was 4 days (SD
6)
Outcomes Survival time from admission to the hospice. Median time was 12 days in sedated group
and 9 days in non-sedated group. No other outcomes of this review were reported
Notes Funding: Istituto Oncological Romagnolo, Forli and Istituto Scientifico Romagnolo per
lo Studio e la Cura dei Tumori
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No randomisation or other allocation to
treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of treatment group possible
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes data collected from medical
records. However, survival is an objective
outcome
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Maltoni 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants reported (consecutive case
series)
Selective reporting (reporting bias) Low risk No evidence of outcomes being measured
but not reported
Similarity of baseline characteristics High risk Matching was used to ensure baseline
comparability on demographic variables.
There were more people with uncontrol-
lable symptoms in the sedated group (57%)
compared with the non-sedated group
(49%)
Similarity of outcomes at baseline Unclear risk Baseline comparison of outcomes not pos-
sible (survival)
Maltoni 2012b
Methods Design: prospective, non-randomised cohort study from October 2009 to June 2010
comparing people who received palliative sedation with people who did not
Setting: 2 palliative care units in Italy
Participants 327 consecutive participants; 72 (22%) received palliative sedation. Indications for pal-
liative sedation were delirium (61%), existential distress (38%), dyspnoea (29%), pain
(21%), and other reason (8%)
Interventions 96% achieved sedation with midazolam, 4% with another benzodiazepine. Mean dura-
tion of sedation was 32.2 hours (range 25-253)
Outcomes Survival time from admission to the unit. Mean time was 11 days in sedated group and
9 days in non-sedated group. Change in overall symptoms was reported only for the
sedated group
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No randomisation or other allocation to
treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of treatment group possible
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Maltoni 2012b (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes data collected from prospective
database records. However, survival is an
objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants reported (consecutive case
series)
Selective reporting (reporting bias) Low risk No evidence of outcomes being measured
but not reported
Similarity of baseline characteristics Unclear risk No baseline comparison of groups given
Similarity of outcomes at baseline Unclear risk Baseline comparison of outcome not pos-
sible (survival)
Muller-Busch 2003
Methods Design: retrospective chart review of consecutive case series in 1995-2002 comparing
people who received palliative sedation with people who did not
Setting: palliative care unit in Germany
Participants 548 people who died in the palliative care unit; 10.5% had a non-cancer diagnosis; 80
(15%) received palliative sedation
Interventions Protocol for palliative sedation not reported, although the unit had general guidelines
for the initiation and maintenance of sedation. Sedation was achieved with midazolam
in most cases
Outcomes Survival time from admission to the palliative care unit: Median 14.0 days and mean 21.
1 (SD 23.6) days in the non-sedated group, and median 15.5 days and mean 21.5 (SD
21.1) days in the sedated group. Symptom prevalence was reported at admission, during
the course of admission, and in the last 48 hours before death. No other outcomes of
this review were reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No randomisation or other allocation to
treatment group
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Muller-Busch 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of treatment group possible
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes data collected from medical
records. Survival is an objective outcome;
however, we judged symptom control out-
come at high risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants reported (consecutive case
series)
Selective reporting (reporting bias) Low risk No evidence of outcomes being measured
but not reported
Similarity of baseline characteristics High risk Sedated group significantly younger, and
some differences in disease stage and cancer
site
Similarity of outcomes at baseline Unclear risk Baseline comparison of outcome (survival)
not possible. Baseline differences in propor-
tions with pain, dyspnoea, anxiety (higher
in sedated group), and delirium (lower in
sedated group)
Radha Krishna 2012
Methods Design: retrospective chart review of consecutive case series from September 2006 to
September 2007, comparing people who received palliative sedation with people who
did not
Setting: oncology ward in a tertiary care hospital in Singapore
Participants 238 people with cancer; 68 (29%) received palliative sedation. Indications for sedation
were anxiety (24%); dyspnoea (21%); agitation (19%); nausea (18%); dyspnoea and
anxiety (9%); agitation and nausea (3%); confusion (3%); stiffness (3%); dyspnoea,
anxiety, and stiffness (1%)
Interventions Protocol for palliative sedation not reported. Sedation was achieved with either midazo-
lam (57% of participants) or haloperidol (43%). Duration of sedative use not reported
Outcomes Survival time from admission to the ward was reported in graphical form, and was
not statistically significantly different between the sedated and non-sedated groups (P
value = 0.78, log-rank test). No median survival times were reported, but they were
approximately 8 days in both groups (interpolated from survival curves)
Notes
Risk of bias
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Radha Krishna 2012 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No randomisation or other allocation to
treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of treatment group possible
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes data collected from medical
records. However, survival is an objective
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants reported (consecutive case
series)
Selective reporting (reporting bias) Low risk No evidence of outcomes being measured
but not reported
Similarity of baseline characteristics Unclear risk No baseline comparison of groups given
Similarity of outcomes at baseline Unclear risk Baseline comparison of outcome not pos-
sible (survival)
Rietjens 2008
Methods Design: retrospective chart review of consecutive case series comparing people who re-
ceived palliative sedation with people who did not
Setting: acute palliative care unit in an academic cancer hospital in The Netherlands
Participants 753 people with cancer; 157 people died and were included in the analysis. 68 (43%)
received palliative sedation. Indications for sedation were terminal restlessness (62%),
dyspnoea (47%), pain (26%), and anxiety (6%)
Interventions Protocol for palliative sedation not reported. 75% received midazolam, 1% midazolam
plus another benzodiazepine, 9% midazolam plus propofol, and 15% propofol only.
Median duration of sedation was 19 hours (range 1-125)
Outcomes Survival time from admission to the palliative care unit. Median time was 8 days in
sedated group and 7 days in non-sedated group. Symptom control was recorded at 0-
24 hours before death and 25-48 hours before death comparing the non-sedated group
with people who began sedation at these time points. No other outcomes of this review
were reported
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Rietjens 2008 (Continued)
Notes Declarations of interest: the authors stated that they “confirm that there are nofinancial or
personal relationships with other people or organisations that could have inappropriately
influenced the work”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No randomisation or other allocation to
treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of treatment group possible
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes data collected from medical
records. However, survival is an objective
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants reported (consecutive case
series)
Selective reporting (reporting bias) Low risk No evidence of outcomes being measured
but not reported
Similarity of baseline characteristics High risk Baseline comparison of demographic vari-
ables and symptoms was reported. Sedated
participants were significantly younger,
more had gastrointestinal tumours, and a
shorter time to admission since diagnosis
of metastatic tumours
Similarity of outcomes at baseline Unclear risk At baseline, symptom prevalence was simi-
lar in the 2 groups. Baseline comparison of
other outcomes not possible (survival)
Stone 1997
Methods Design: retrospective chart review of consecutive case series, comparing people who
received palliative sedation with people who did not
Setting: hospital support team and hospice in London, UK (January to December 1994
for the support team, February 1995 for the hospice)
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Stone 1997 (Continued)
Participants 115 people; 30 (26%) received palliative sedation for uncontrollable symptoms. Indica-
tions for sedation were agitated delirium (18), mental anguish (8), pain (6), dyspnoea
(6), and other (1). No description of clinical diagnoses reported. Another group of par-
ticipants received some sedative medications, but it appeared the indication was not for
otherwise intractable symptoms
Interventions Protocol for palliative sedation not reported. 80% receivedmidazolam, 37% haloperidol,
33% methotrimeprazine, and 3% phenobarbitone. Mean duration of sedation was 1.
3 days. Mean doses of drugs on the day of death were midazolam 22 mg/24 hour,
methotrimeprazine 64 mg/24 hour, and haloperidol 5 mg/24 hour
Outcomes Survival time from admission to the support team or hospice. Mean time was 18.6 days
in sedated group and 19.1 days in non-sedated group. No other outcomes of this review
were reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No randomisation or other allocation to
treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of treatment group possible
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes data collected from medical
records. However, survival is an objective
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants reported (consecutive case
series)
Selective reporting (reporting bias) Low risk No evidence of outcomes being measured
but not reported
Similarity of baseline characteristics Unclear risk Baseline comparison of groups only given
for age and gender (not significantly differ-
ent)
Similarity of outcomes at baseline Unclear risk Baseline comparison of other outcomes not
possible (survival)
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Sykes 2003
Methods Design: retrospective chart review of consecutive case series in 1999 comparing people
who received palliative sedation with people who did not
Setting: hospice in UK
Participants 237 consecutive participants who died in the hospice; 64 (27%) received palliative
sedation in the last 48 hours of life; another 16 (7%) received palliative sedation for the
last 7 days of life. These were compared with people receiving no sedation or very low
doses
Interventions Midazolamwas used inmost participants, with somepeople receivingmethotrimeprazine
or haloperidol
Outcomes Survival time from admission to hospice. Mean time was 14.3 days (95% CI 11.2 to
17.4) in sedation in the last 48 hours of life group, 36.6 days (95% CI 31.5 to 41.7) in
sedation for the last 7 days of life group, and 14.2 days (95% CI 12.7 to 15.7) in non-
sedated group. No other outcomes of this review were reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No randomisation or other allocation to
treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of treatment group possible
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes data collected from medical
records. However, survival is an objective
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants reported (consecutive case
series)
Selective reporting (reporting bias) Low risk No evidence of outcomes being measured
but not reported
Similarity of baseline characteristics Unclear risk No baseline comparison of groups given
Similarity of outcomes at baseline Unclear risk Baseline comparison of outcome not pos-
sible (survival)
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Vitetta 2005
Methods Design: retrospective chart review of consecutive case series, comparing people who
received palliative sedation with people who did not
Setting: hospice with dedicated palliative care beds in Melbourne, Australia
Participants 102 people; 92% had cancer; 68 (67%) received sedation. Uncontrollable symptoms that
led to sedation were not stated. Terminal agitation developed in 38% after admission
and 26% developed anxiety/depression
Interventions 41% received haloperidol, 34% midazolam, and 28% clonazepam. Mean duration of
sedation not reported. Median doses of drugs on the day of death were midazolam 15
mg/24 hour, haloperidol 5 mg/24 hour, and clonazepam 2 mg/24 hour
Outcomes Survival time from admission to the hospice. Mean time was 36.5 days in sedated group
and 17.0 days in non-sedated group. No other outcomes of this review were reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No randomisation or other allocation to
treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of treatment group possible
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes data collected from medical
records. However, survival is an objective
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants reported (consecutive case
series)
Selective reporting (reporting bias) Low risk No evidence of outcomes being measured
but not reported
Similarity of baseline characteristics Unclear risk Baseline comparison of groups for demo-
graphic variables not reported
Similarity of outcomes at baseline Unclear risk Baseline comparison of survival outcome
not possible
CI: confidence interval; NIH: National Institutes of Health; SD: standard deviation.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Cameron 2004 No comparison between sedated and non-sedated people
Claessens 2012 No comparison between sedated and non-sedated people
Cowan 2006 No comparison between sedated and non-sedated people, except on participant characteristics
Da Costa Miranda 2011 No comparison between sedated and non-sedated people
Fainsinger 2000 No comparison between sedated and non-sedated people
Good 2005 No comparison between sedated and non-sedated people
Mercandante 2009 No comparison between sedated and non-sedated people, except on participant characteristics
Morita 2005 No comparison between sedated and non-sedated people
Porzio 2010 No comparison between sedated and non-sedated people
Rosengarten 2009 No comparison between sedated and non-sedated people
van Dooren 2009 No comparison between sedated and non-sedated people
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL
#1MeSH descriptor: [Central Nervous System Depressants] explode all trees
#2MeSH descriptor: [Anesthesia] explode all trees
#3MeSH descriptor: [Benzodiazepines] explode all trees
#4MeSH descriptor: [Barbiturates] explode all trees
#5MeSH descriptor: [Histamine Antagonists] explode all trees
#6MeSH descriptor: [Psychotropic Drugs] explode all trees
#7(benzodiazepine* or barbiturate* or anaesthesia or anesthesia or opioid* or antipsychotic* or anti-psychotic* or antihistamine* or
anti-histamine* or hypnotic* or sedat* or tranquil*):ti,ab,kw (Word variations have been searched)
#8(symptom* near/6 (relie* or control*)):ti,ab,kw (Word variations have been searched)
#9#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
#10MeSH descriptor: [Palliative Care] this term only
#11MeSH descriptor: [Terminal Care] explode all trees
#12MeSH descriptor: [Terminally Ill] this term only
#13palliat*:ti,ab,kw (Word variations have been searched)
#14(terminal* near/6 (care or caring or ill*)):ti,ab,kw (Word variations have been searched)
#15(terminal-stage* or terminal stage* or dying or (close near/6 death)):ti,ab,kw (Word variations have been searched)
#16(end near/3 life):ti,ab,kw (Word variations have been searched)
#17hospice*:ti,ab,kw (Word variations have been searched)
#18((end-stage* or end stage*) near/6 (disease* or ill* or care or caring)):ti,ab,kw (Word variations have been searched)
#19((incurable or advanced) near/6 (ill* or disease*)):ti,ab,kw (Word variations have been searched)
#20#10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19
#21#20 and #9
MEDLINE (Ovid)
1 exp Central Nervous System Depressants/
2 exp Anesthesia/
3 exp Benzodiazepines/
4 exp Barbiturates/
5 exp Histamine Antagonists/
6 exp Psychotropic Drugs/
7 (benzodiazepine* or barbiturate* or anaesthesia or anesthesia or opioid* or antipsychotic* or anti-psychotic* or antihistamine* or
anti-histamine* or hypnotic* or sedat* or tranquil*).mp.
8 (symptom* adj6 (relie* or control*)).mp.
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10 Palliative Care/
11 exp Terminal Care/
12 Terminally Ill/
13 palliat*.mp.
14 (terminal* adj6 (care or caring or ill*)).mp.
15 (terminal-stage* or terminal stage* or dying or (close adj6 death)).mp.
16 (end adj3 life).mp.
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17 hospice*.mp.
18 ((end-stage* or end stage*) adj6 (disease* or ill* or care or caring)).mp.
19 ((incurable or advanced) adj6 (ill* or disease*)).mp.
20 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19
21 9 and 20
22 randomized controlled trial.pt.
23 controlled clinical trial.pt.
24 randomized.ab.
25 placebo.ab.
26 clinical trials as topic.sh.
27 randomly.ab.
28 trial.ti.
29 exp Cohort Studies/
30 (cohort* or observational* or comparative* or quantitative* or (before and after) or (interrupted and time)).mp.
31 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
32 21 and 31
EMBASE (Ovid)
1 exp Central Nervous System Depressants/
2 exp Anesthesia/
3 exp Benzodiazepines/
4 exp Barbiturates/
5 exp Histamine Antagonists/
6 exp Psychotropic Drugs/
7 (benzodiazepine* or barbiturate* or anaesthesia or anesthesia or opioid* or antipsychotic* or anti-psychotic* or antihistamine* or
anti-histamine* or hypnotic* or sedat* or tranquil*).tw.
8 (symptom* adj6 (relie* or control*)).tw.
9 or/1-8
10 Palliative Care/
11 exp Terminal Care/
12 Terminally Ill/
13 palliat*.tw.
14 (terminal* adj6 (care or caring or ill*)).tw.
15 (terminal-stage* or terminal stage* or dying or (close adj6 death)).tw.
16 (end adj3 life).tw.
17 hospice*.tw.
18 ((end-stage* or end stage*) adj6 (disease* or ill* or care or caring)).tw.
19 ((incurable or advanced) adj6 (ill* or disease*)).tw.
20 or/10-19
21 9 and 20
22 “randomized controlled trial”.tw.
23 “controlled clinical trial”.tw.
24 randomized.ab.
25 placebo.ab.
26 “clinical trial (topic)”/
27 randomly.ab.
28 trial.ti.
29 exp Cohort Studies/
30 (cohort* or observational* or comparative* or quantitative* or (before and after) or (interrupted and time)).mp.
31 or/22-30
32 21 and 31
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WH A T ’ S N E W
Date Event Description
17 January 2017 Review declared as stable See Published notes.
C O N T R I B U T I O N S O F A U T H O R S
Draft the protocol: Elaine Beller (EB), Mieke van Driel (MvD), Geoffrey Mitchell (GM).
Study selection: EB, MvD, GM as arbiter.
Extract data from studies: LM, ST, EB as arbiter.
Enter data into Review Manager 5 (RevMan 2014): EB.
Carry out the analysis: EB.
Interpret the analysis: EB, MvD, GM.
Write the final review: EB, MvD, GM, LM, ST.
Update the review: EB, MvD, GM.
D E C L A R A T I O N S O F I N T E R E S T
EB has no known conflicts of interest to declare that are relevant to this review.
MvD has no known conflicts of interest to declare that are relevant to this review.
LM has no known conflicts of interest to declare that are relevant to this review.
ST has no known conflicts of interest to declare that are relevant to this review.
GM has no known conflicts of interest to declare that are relevant to this review.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
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External sources
• Funded in part by a National Health and Medical Research Council grant #527500, Australia.
• NIHR Cochrane Incentive Scheme 2013, UK.
Award Reference Number:14/175/01
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
None noted. Where we planned other analyses, but were unable to perform them, we noted this in the text.
N O T E S
A restricted search in January 2017 did not identify any potentially relevant studies likely to change the conclusions, although we are
aware of one large study due to be published in 2017. Therefore, following discussion with the authors and editors, this review has
now been stabilised for 12 months, at which point we will assess the review for updating.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Terminally Ill; Conscious Sedation [∗mortality]; Deep Sedation [∗mortality]; Hypnotics and Sedatives [∗administration & dosage;
adverse effects]; Palliative Care [∗methods]; Selection Bias; Terminal Care [∗methods]
MeSH check words
Adult; Humans
40Palliative pharmacological sedation for terminally ill adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
